Dolly Vance | Executive Vice President, Corporate Affairs and General Counsel |
Raul Rodriguez | President and Chief Executive Officer |
Anne-Marie Duliege | Executive Vice President and Chief Medical Officer |
Eldon Mayer | Executive Vice President and Chief Commercial Officer |
Nelson Cabatuan | Vice President, Finance |
Kyung Yang | Jefferies LLC |
Tessa Romero | J.P. Morgan Securities, LLC |
Do Kim | BMO Capital Markets Corp. |
Joseph Pantginis | H.C. Wainwright & Co. |
Elemer Piros | Cantor Fitzgerald & Co. |
Good afternoon, and welcome to Rigel Pharmaceuticals' Financial Conference Call for the Fourth Quarter and Year End of 2017. All participants are in a listen-only mode.
We will be facilitating a question-and-answer session at the end of today's conference. [Operator Instructions] I would like to remind you that this call is being recorded for replay purposes from Rigel's website. [Operator Instructions] And now, I would turn this conference over to our first speaker, Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel.